DE60319686D1 - Cyanamide als reversible hemmer von cystein proteasen - Google Patents

Cyanamide als reversible hemmer von cystein proteasen

Info

Publication number
DE60319686D1
DE60319686D1 DE60319686T DE60319686T DE60319686D1 DE 60319686 D1 DE60319686 D1 DE 60319686D1 DE 60319686 T DE60319686 T DE 60319686T DE 60319686 T DE60319686 T DE 60319686T DE 60319686 D1 DE60319686 D1 DE 60319686D1
Authority
DE
Germany
Prior art keywords
hemmer
cyanamide
reversible
cystein proteases
cysteine proteases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60319686T
Other languages
English (en)
Other versions
DE60319686T2 (de
Inventor
Weimin Liu
Thomas A Gilmore
E R Hickey
P A Nemoto
D M Spero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharmaceuticals Inc
Publication of DE60319686D1 publication Critical patent/DE60319686D1/de
Application granted granted Critical
Publication of DE60319686T2 publication Critical patent/DE60319686T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C261/00—Derivatives of cyanic acid
    • C07C261/04—Cyanamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DE60319686T 2002-04-05 2003-04-01 Cyanamide als reversible hemmer von cystein proteasen Expired - Fee Related DE60319686T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37036802P 2002-04-05 2002-04-05
US370368P 2002-04-05
PCT/US2003/009852 WO2003086325A2 (en) 2002-04-05 2003-04-01 Cyanamides useful as reversible inhibitors of cysteine proteases

Publications (2)

Publication Number Publication Date
DE60319686D1 true DE60319686D1 (de) 2008-04-24
DE60319686T2 DE60319686T2 (de) 2009-04-16

Family

ID=29250518

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60319686T Expired - Fee Related DE60319686T2 (de) 2002-04-05 2003-04-01 Cyanamide als reversible hemmer von cystein proteasen

Country Status (8)

Country Link
EP (1) EP1495009B1 (de)
JP (1) JP2005522489A (de)
AT (1) ATE388946T1 (de)
AU (1) AU2003230772A1 (de)
CA (1) CA2477692A1 (de)
DE (1) DE60319686T2 (de)
ES (1) ES2301793T3 (de)
WO (1) WO2003086325A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076796A1 (en) * 2005-01-19 2006-07-27 Merck Frosst Canada Ltd. Cathepsin k inhibitors and obesity
US8497271B2 (en) 2009-10-07 2013-07-30 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8304577B2 (en) 2009-10-09 2012-11-06 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
CN105121445A (zh) 2013-02-22 2015-12-02 百时美施贵宝公司 作为连接蛋白相关激酶1(AAK1)抑制剂的5H-色烯并[3,4-c]吡啶
US10253027B2 (en) 2013-07-08 2019-04-09 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US10174044B2 (en) 2015-04-10 2019-01-08 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1155010A1 (de) * 1999-02-20 2001-11-21 AstraZeneca AB Acetamido-acetonitril-derivate als cathepsin l- oder cathepsin s-inhibitoren
AU2001256981A1 (en) * 2000-04-06 2001-10-23 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors

Also Published As

Publication number Publication date
ES2301793T3 (es) 2008-07-01
EP1495009A2 (de) 2005-01-12
DE60319686T2 (de) 2009-04-16
WO2003086325A2 (en) 2003-10-23
WO2003086325A3 (en) 2004-07-01
AU2003230772A1 (en) 2003-10-27
ATE388946T1 (de) 2008-03-15
EP1495009B1 (de) 2008-03-12
AU2003230772A8 (en) 2003-10-27
CA2477692A1 (en) 2003-10-23
JP2005522489A (ja) 2005-07-28

Similar Documents

Publication Publication Date Title
DE60231207D1 (de) Inhibitoren
MY132419A (en) Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
DE60319686D1 (de) Cyanamide als reversible hemmer von cystein proteasen
ATE516062T1 (de) Quaternäre ammoniumverbindungen enthaltende wasserfreie zusammensetzungen
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
WO1999024460A3 (en) Dipeptide nitriles
DE60321141D1 (en) Cathepsin-cystein-protease-hemmer
EA200300970A1 (ru) Энантиоселективный синтез промежуточных соединений для получения азетидинонов
DE60330407D1 (de) Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
CA2121523A1 (en) Sulfonamide derivatives
SG146658A1 (en) Haloalkyl containing compounds as cysteine protease inhibitors
BR0300709A (pt) Sal de perindopril e as composições farmacêuticas contendo o mesmo
SE0301368D0 (sv) Chemical compounds
DE602004029355D1 (de) Sulfopyrrolderivate
ATE365702T1 (de) Eisenoxide mit höherem veredelungsgrad
AP2000001992A0 (en) Succinamide inhibitors of inteleukin-1B converting enzyme.
TR200302296T4 (tr) 20 ppm klor iyonundan daha çok ihtiva eden kararlı gabapentin
DE69610978D1 (de) 4-substituierte-3-peptidyl-azetidin-2-on-derivate als cystein-proteinase inhibitoren
WO2004110374A3 (en) 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
ATE472326T1 (de) Neue zyklische harnstoffe als inhibitoren von metalloproteasen
IL153830A0 (en) A PROCESS FOR THE PREPARATION OF alpha' CHLOROKETONES
MXPA03001272A (es) Procedimiento para la preparacion de dinapsolina.
DE602005017879D1 (de) Nichtpeptidinhibitoren von matrixmetalloproteinasen
DE60204046D1 (de) N-heterocyclylhydrazide als neurotrophe mittel
ATE400580T1 (de) Chemische synthese von solamargin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee